EDN1 and acute respiratory distress syndrome: Our data demonstrated therapeutic effects of CsnB against ARDS and that downregulation of ET-1 may contribute to suppression of pulmonary neutrophilic inflammation by CsnB, resulting in alleviation of endothelial-epithelial barrier dysfunction and improvement of hypoxemia and multiple organ injury.